Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01903733




Registration number
NCT01903733
Ethics application status
Date submitted
16/07/2013
Date registered
19/07/2013
Date last updated
19/07/2022

Titles & IDs
Public title
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Scientific title
AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008
Secondary ID [1] 0 0
2013-000691-15
Secondary ID [2] 0 0
B1871040
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Myeloid Leukemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - bosutinib

Treatment: Drugs: bosutinib
The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) (Version 3.0)
Timepoint [1] 0 0
From first dose of drug up to 30 days after last dose (up to approximately 14 years)
Primary outcome [2] 0 0
Number of Participants With Grade 3 or 4 Treatment-Emergent Adverse Events (AEs) Based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) (Version 3.0)
Timepoint [2] 0 0
From first dose of drug up to 30 days after last dose (up to approximately 14 years)
Primary outcome [3] 0 0
Number of Participants With Treatment-Emergent Treatment Related Adverse Events (AEs) Based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) (Version 3.0)
Timepoint [3] 0 0
From first dose of drug up to 30 days after last dose (up to approximately 14 years)
Primary outcome [4] 0 0
Number of Participants With Laboratory Test Abnormalities Based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) (Version 4.03)
Timepoint [4] 0 0
From first dose of drug up to 30 days after last dose (up to approximately 14 years)
Primary outcome [5] 0 0
Number of Participants With Adverse Events as Reason for Treatment Discontinuation
Timepoint [5] 0 0
From first dose of drug up to 30 days after last dose (up to approximately 14 years)
Primary outcome [6] 0 0
Number of Participants With Diarrhea After Switch From Bosutinib Clinical Formulation to Bosutinib Commercial Formulation
Timepoint [6] 0 0
Last 6 months on clinical formulation and first 6 months on commercial formulation
Primary outcome [7] 0 0
Number of Participants With Breakpoint Cluster Region Abelson Protooncogene (BCR-ABL) Mutations Present at Time of Bosutinib Treatment Discontinuation
Timepoint [7] 0 0
Post-baseline on Day 1 (maximum up to 14 years)
Primary outcome [8] 0 0
Overall Survival (OS) Rate at Year 10
Timepoint [8] 0 0
Year 10
Primary outcome [9] 0 0
Plasma Steady-State Trough Concentrations (Ctrough) of Bosutinib
Timepoint [9] 0 0
One pre-dose sample was collected at the first scheduled visit (after approval and implementation of protocol amendment 1) following at least 2 weeks of uninterrupted dosing at the same dose level
Primary outcome [10] 0 0
Kaplan-Meier Estimate of Probability of Maintaining Major Cytogenetic Response (MCyR) at Year 10: B1871006 Participants
Timepoint [10] 0 0
Year 10
Primary outcome [11] 0 0
Kaplan-Meier Estimate of Probability of Maintaining Complete Cytogenetic Response (CCyR) at Year 10: B1871006 Participants
Timepoint [11] 0 0
Year 10
Primary outcome [12] 0 0
Kaplan-Meier Estimate of Probability of Maintaining Complete Hematologic Response (CHR) at Year 10: B1871006 Participants
Timepoint [12] 0 0
Year 10
Primary outcome [13] 0 0
Cumulative Incidence of Progression/Death Events at Year 10: B1871006 Participants
Timepoint [13] 0 0
Year 10
Primary outcome [14] 0 0
Cumulative Incidence of Rate of Transformation to Accelerated Phase (AP) or Blast Phase (BP) at Year 10: B1871006 Participants
Timepoint [14] 0 0
Year 10

Eligibility
Key inclusion criteria
* Only subjects previously participating in two specific studies are eligible to enroll into this study. Enrollment is not open to subjects if not previously enrolled in studies B1871006 or B1871008.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* All subjects are excluded unless previously participating in studies B1871006 or B1871008.

Study design
Purpose of the study
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/08/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/06/2020
Sample size
Target
Accrual to date
Final
281
Recruitment in Australia
Recruitment state(s)
QLD,SA
Recruitment hospital [1] 0 0
Royal Brisbane & Women's Hospital - Herston
Recruitment hospital [2] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 0 0
4029 - Herston
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Georgia
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Iowa
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
Argentina
State/province [9] 0 0
Buenos Aires
Country [10] 0 0
Argentina
State/province [10] 0 0
Corrientes
Country [11] 0 0
Belgium
State/province [11] 0 0
Charleroi
Country [12] 0 0
Brazil
State/province [12] 0 0
SP
Country [13] 0 0
Canada
State/province [13] 0 0
Alberta
Country [14] 0 0
Canada
State/province [14] 0 0
British Columbia
Country [15] 0 0
Canada
State/province [15] 0 0
Ontario
Country [16] 0 0
Canada
State/province [16] 0 0
Quebec
Country [17] 0 0
Chile
State/province [17] 0 0
V Region
Country [18] 0 0
China
State/province [18] 0 0
Beijing
Country [19] 0 0
China
State/province [19] 0 0
Zhejiang
Country [20] 0 0
China
State/province [20] 0 0
Shanghai
Country [21] 0 0
China
State/province [21] 0 0
Tianjin
Country [22] 0 0
Colombia
State/province [22] 0 0
Cundinamarca
Country [23] 0 0
Finland
State/province [23] 0 0
Helsinki
Country [24] 0 0
France
State/province [24] 0 0
Caen Cedex 9
Country [25] 0 0
France
State/province [25] 0 0
Nantes cedex 1
Country [26] 0 0
France
State/province [26] 0 0
Poitiers Cedex
Country [27] 0 0
France
State/province [27] 0 0
Poitiers
Country [28] 0 0
France
State/province [28] 0 0
Strasbourg
Country [29] 0 0
Hong Kong
State/province [29] 0 0
Chai Wan
Country [30] 0 0
Hong Kong
State/province [30] 0 0
Shatin, New Territories
Country [31] 0 0
Hungary
State/province [31] 0 0
Budapest
Country [32] 0 0
Hungary
State/province [32] 0 0
Kaposvar
Country [33] 0 0
India
State/province [33] 0 0
Tamil NADU
Country [34] 0 0
Italy
State/province [34] 0 0
BO
Country [35] 0 0
Italy
State/province [35] 0 0
Monza AND Brianza
Country [36] 0 0
Italy
State/province [36] 0 0
TO
Country [37] 0 0
Italy
State/province [37] 0 0
Roma
Country [38] 0 0
Japan
State/province [38] 0 0
Aichi
Country [39] 0 0
Japan
State/province [39] 0 0
Akita
Country [40] 0 0
Japan
State/province [40] 0 0
Fukuoka
Country [41] 0 0
Japan
State/province [41] 0 0
Ishikawa
Country [42] 0 0
Japan
State/province [42] 0 0
Osaka
Country [43] 0 0
Japan
State/province [43] 0 0
Shizuoka
Country [44] 0 0
Japan
State/province [44] 0 0
Tokyo
Country [45] 0 0
Korea, Republic of
State/province [45] 0 0
Seoul
Country [46] 0 0
Latvia
State/province [46] 0 0
Riga
Country [47] 0 0
Netherlands
State/province [47] 0 0
Amsterdam
Country [48] 0 0
Netherlands
State/province [48] 0 0
Groningen
Country [49] 0 0
Peru
State/province [49] 0 0
Lima
Country [50] 0 0
Poland
State/province [50] 0 0
Gdansk
Country [51] 0 0
Poland
State/province [51] 0 0
Krakow
Country [52] 0 0
Poland
State/province [52] 0 0
Lublin
Country [53] 0 0
Russian Federation
State/province [53] 0 0
Sverdlovsk Region
Country [54] 0 0
Russian Federation
State/province [54] 0 0
Moscow
Country [55] 0 0
Russian Federation
State/province [55] 0 0
Rostov-on-Don
Country [56] 0 0
Russian Federation
State/province [56] 0 0
Saint Petersburg
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Samara
Country [58] 0 0
Singapore
State/province [58] 0 0
Singapore
Country [59] 0 0
South Africa
State/province [59] 0 0
Gauteng
Country [60] 0 0
Spain
State/province [60] 0 0
Barcelona
Country [61] 0 0
Spain
State/province [61] 0 0
Madrid
Country [62] 0 0
Spain
State/province [62] 0 0
Toledo
Country [63] 0 0
Spain
State/province [63] 0 0
Valencia
Country [64] 0 0
Thailand
State/province [64] 0 0
Bangkok
Country [65] 0 0
Turkey
State/province [65] 0 0
Sehit Kamil
Country [66] 0 0
Turkey
State/province [66] 0 0
Ankara
Country [67] 0 0
Ukraine
State/province [67] 0 0
Cherkasy
Country [68] 0 0
Ukraine
State/province [68] 0 0
Dnipropetrovsk
Country [69] 0 0
Ukraine
State/province [69] 0 0
Kyiv
Country [70] 0 0
Ukraine
State/province [70] 0 0
Lviv
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Newcastle Upon Tyne
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Nottinhgam

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.
Trial website
https://clinicaltrials.gov/study/NCT01903733
Trial related presentations / publications
Takahashi N, Cortes JE, Sakaida E, Ishizawa K, Ono T, Doki N, Matsumura I, Garcia-Gutierrez V, Rosti G, Ono C, Ohkura M, Tanetsugu Y, Viqueira A, Brummendorf TH. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. Int J Hematol. 2022 Jun;115(6):838-851. doi: 10.1007/s12185-022-03314-y. Epub 2022 Mar 2.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01903733